Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Pearl Toh, 14 Nov 2020
Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

RA patients on low-dose glucocorticoids at greater risk of serious infection

28 Sep 2020

Long-term use of low-dose glucocorticoids results in a dose-dependent increase in the risk of serious infection in patients with rheumatoid arthritis (RA) on stable disease-modifying antirheumatic drug (DMARD) regimen, with small but significant risk even at doses of 5 mg/day, a study has shown.

“Clinicians should balance the benefits of low-dose glucocorticoids with this potential risk,” according to the authors.

This retrospective cohort study identified adults with RA receiving a stable DMARD therapy for >6 months using Medicare claims data and Optum’s deidentified Clinformatics Data Mart database from 2006 to 2015.

Inverse probability–weighted analyses, with 1-year cumulative incidence predicted from weighted models, were performed to examine the associations between glucocorticoid dose (none, ≤5, >5 to 10, and >10 mg/d) and hospitalized infection.

Overall, 247,297 observations have been identified from 172,041 Medicare patients and 58,279 observations among 44,118 patients in Optum. Glucocorticoids were given to 47.1 percent of Medicare patients and 39.5 percent of Optum patients after 6 months of stable DMARD use.

The 1-year cumulative incidence of hospitalized infection in Medicare patients not on glucocorticoids was 8.6 percent compared with 11.0 percent (95 percent confidence interval [CI], 10.6–11.5) for glucocorticoid dose of 5 mg/day, 14.4 percent (95 percent CI, 13.8–15.1) for >5 to 10 mg/day, and 17.7 percent (95 percent CI, 16.5–19.1) for >10 mg/day (p<0.001 for all vs no glucocorticoids).

In Optum patients not receiving glucocorticoids, the 1-year cumulative incidence of hospitalized infection was 4.0 percent relative to 5.2 percent (95 percent CI, 4.7–5.8) for glucocorticoid dose of 5 mg/day, 8.1 percent (95 percent CI, 7.0–9.3) for >5 to 10 mg/day, and 10.6 percent (95 percent CI, 8.5–13.2) for >10 mg/day (p<0.001 for all vs no glucocorticoids).

This study was limited by potential residual confounding and misclassification of glucocorticoid dose.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Pearl Toh, 14 Nov 2020
Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.